Lara Pharm
Cannabinoid-based Pharmaceuticals
Company Overview
Snapshot
Founded in November 2010 by Rita Alter, Lara Pharm operated with 1–10 employees. The company was acquired by SciSparc in August 2014, marking a significant milestone in its trajectory.
Business overview
Lara Pharm develops pharmaceutical-grade cannabinoids and related technology, focusing on creating standardized cannabis-based prescription drugs. The company aims to provide alternatives to medical marijuana through innovations like an inhaler designed to deliver controlled doses of cannabinoids. Lara Pharm operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Medical Devices markets, with a focus on Medical Cannabis and Drug Delivery.
Strategic signal
In January 2015, Lara Pharm's dry-powder inhaler for cannabis delivery was highlighted, signaling the company's focus on advanced pharmaceutical applications for cannabinoids. This development underscored the potential for precise, medical-grade cannabis administration, positioning the company as an innovator in the evolving medical cannabis and drug delivery landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Lara Pharm's primary focus?
- Lara Pharm focuses on developing pharmaceutical-grade cannabinoids and related technology, aiming to create standardized cannabis-based prescription drugs.
- When was Lara Pharm acquired and by whom?
- Lara Pharm was acquired by SciSparc in August 2014.
- Who founded Lara Pharm?
- Lara Pharm was founded by Rita Alter.
- What specific product did Lara Pharm develop?
- Lara Pharm developed an inhaler designed to deliver a controlled dose of cannabinoids.
- What was a notable product development for Lara Pharm?
- In January 2015, Lara Pharm's dry-powder inhaler for cannabis delivery was featured, showcasing its approach to medical cannabis administration.